PT-141, also known as Bremelanotide, is a synthetic peptide derived from the melanocortin receptor agonist Melanotan II. While Melanotan II was originally studied for its pigmentation effects, PT-141 emerged during research as a potent compound for influencing sexual arousal and libido — particularly via neurological pathways. Unlike PDE5 inhibitors (such as Viagra), PT-141 works directly on the brain to stimulate desire, offering a unique mechanism of action that has garnered considerable attention in both research and clinical settings.

This product is for laboratory research purposes only and is not approved for human use. PT-141 is sold as a lyophilized powder intended for reconstitution in sterile solvent and research under appropriate conditions.

Mechanism of Action:

PT-141 works primarily by activating melanocortin receptors in the central nervous system, particularly MC3R and MC4R. These receptors are known to be involved in several physiological functions, including:

• Sexual arousal and desire

• Appetite regulation

• Mood balance

• Energy homeostasis

Unlike PDE5 inhibitors, PT-141 does not target the vascular system or require sexual stimulation to induce arousal. Instead, it works by stimulating the hypothalamus, directly affecting libido. In animal studies, PT-141 induced spontaneous erections and increased sexual activity even in the absence of external stimuli.

Theoretical Benefits of PT-141:

All benefits described are based on preclinical and clinical research and are not approved indications. This compound is for research use only.

1. Increased Libido:

PT-141 has shown the potential to significantly increase sexual desire in both males and females by acting on neural pathways. In female animal models, the compound has induced sexual readiness, and in male subjects, spontaneous erections were reported without direct genital stimulation.

2. Potential Treatment for Sexual Dysfunction:

In clinical trials, PT-141 has been investigated for its effects on hypoactive sexual desire disorder (HSDD) and erectile dysfunction (ED). Its mechanism is distinct from common ED medications and may benefit individuals unresponsive to PDE5 inhibitors.

3. Improved Arousal Without Cardiovascular Impact:

Because PT-141 doesn’t act via the nitric oxide or vascular pathway, it offers theoretical advantages for patients with cardiovascular conditions who cannot use PDE5 inhibitors.

4. Mood and Energy Effects:

As a melanocortin agonist, PT-141 may influence appetite, mood, and energy levels in animal models. Some researchers are exploring its impact on neurochemical balance and fatigue syndromes.

Clinical Trials and Studies:

• Female Sexual Dysfunction: PT-141 was evaluated in several double-blind, placebo-controlled trials involving premenopausal women with HSDD. Subjects receiving PT-141 reported increased sexual desire and reduced distress related to low libido.

• Erectile Dysfunction: In studies involving men with mild-to-moderate ED, PT-141 administered intranasally or via injection led to rapid onset of erection, independent of visual or tactile stimulation.

• Safety Profile: The compound demonstrated a relatively safe profile in research settings, with the most commonly reported side effects being nausea, flushing, and mild headaches.

• FDA Status: In 2019, the FDA approved Bremelanotide under the brand name Vyleesi for female HSDD. This version differs in formulation and delivery but highlights the strong interest in this peptide’s effects.

Research Dosing Guidelines (Theoretical):

• Research Range: 0.5mg to 2mg per administration

• Frequency: Administered 30–60 minutes prior to test sessions in most studies

• Route: Subcutaneous injection is the most studied method, though intranasal and oral research exists

• Duration: Acute-use models show rapid onset; effects typically last 6–12 hours

• Storage: Lyophilized PT-141 should be refrigerated (2–8°C); once reconstituted, use within 30 days

Potential Side Effects in Research:

In studies and trials involving both men and women, PT-141 showed limited but notable side effects, primarily due to its central action:

• Nausea (mild to moderate, dose-dependent)

• Flushing

• Headache

• Temporary increase in blood pressure (in rare cases)

No significant effects on hormone levels, vision, or cardiovascular function were observed in the majority of trials.

Legal and Safety Disclaimer:

PT-141 is not approved for human or veterinary consumption. This compound is offered strictly for laboratory research purposes and should only be used by qualified professionals in controlled settings. It is the buyer’s responsibility to comply with all local laws regarding peptide handling and usage.